Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with the flu season entering a rapid escalation phase, prompting healthcare professionals to recommend early antiviral treatment for patients [1][2][3]. Group 1: Influenza Activity Trends - The latest report from the Chinese Center for Disease Control and Prevention shows an increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week, and higher than the same period in 2022 and 2024 [2]. - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week (3.7%) and the same period in previous years [2]. - A total of 347 influenza-like illness outbreaks were reported nationwide, with the majority being A(H3N2) strains [2]. Group 2: Treatment Recommendations - Healthcare professionals emphasize the importance of early antiviral treatment within 48 hours of symptom onset, with oseltamivir being the preferred choice for pediatric and immunocompromised patients [4]. - Oseltamivir is currently the only oral medication approved for flu prevention in high-risk groups, requiring administration within 48 hours of exposure [4]. Group 3: Market Dynamics and Drug Approvals - The National Medical Products Administration has approved over 120 registrations for oseltamivir, with companies like Dongyang Sunshine Pharmaceutical holding a significant market share of over 70% in the oseltamivir market [4][5]. - The recent surge in flu cases has led to increased sales of antiviral medications, with companies implementing measures to ensure continuous production [5]. - Several new RNA polymerase inhibitors have been approved, including Marbofloxacin and Favipiravir, expanding treatment options for influenza [6][7]. Group 4: Supply and Demand for Antiviral Medications - Roche reported a significant increase in demand for its antiviral drug, Marbofloxacin, leading to supply pressures, with production ramped up to meet the needs of the flu season [6][7]. - Domestic companies are also advancing their antiviral products, with several new drugs entering the market and participating in national health insurance negotiations [8][9].
门急诊阳性率明显提升，流感药企开启不间断生产模式